Regulatory PathRegulatory requirements compared

Active substance

Edotreotide

Open in the medicines table

EMA European Union — centrally authorised medicines

SomaKit TOC Novartis Europharm Limited · Authorised · authorised 8 Dec 2016 · ATC V09IX

Therapeutic indication (EMA)

This medicinal product is for diagnostic use only. After radiolabelling with gallium (68Ga) chloride solution, the solution of gallium (68Ga) edotreotide obtained is indicated for Positron Emission Tomography (PET) imaging of somatostatin receptor overexpression in adult patients with confirmed or suspected well-differentiated gastro-enteropancreatic neuroendocrine tumours (GEP-NET) for localizing primary tumours and their metastases.

UK MHRA United Kingdom — marketing authorisations

ProductAuthorisationHolderLegal status
SOMAKIT TOC 40MCG KIT FOR RADIOPHARMACEUTICAL PREPARATIONPLGB 00101/1229NOVARTIS PHARMACEUTICALS UK LIMITEDPOM

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), MHRA category lists of UK marketing authorisations (Open Government Licence v3.0), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.